VYNE Therapeutics Inc. (VYNE)
2.98
0.23 (8.36%)
At close: Jan 15, 2025, 10:17 AM
undefined% (undefined)
| Bid | 2.85 |
| Market Cap | 43.96M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | 3.29 |
| PE Ratio (ttm) | 0.91 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 2.99 |
| Volume | 29,513 |
| Avg. Volume (20D) | 123,040 |
| Open | 2.84 |
| Previous Close | 2.75 |
| Day's Range | 2.81 - 2.98 |
| 52-Week Range | 1.57 - 4.30 |
| Beta | undefined |
About VYNE
VYNE Therapeutics Inc., a pharmaceutical company, focuses on developing various therapeutics for the treatment of immuno-inflammatory conditions. The company develops FCD105, a topical combination foam that has completed Phase III clinical trials for the treatment of moderate-to-severe acne vulgaris; and FMX114, a combination of tofacitinib, which is in Phase IIa preclinical trial for the treatment of mild-to-moderate atopic dermatitis. It is als...
Industry Biotechnology
Sector Healthcare
IPO Date Jan 25, 2018
Employees 10
Stock Exchange NASDAQ
Ticker Symbol VYNE
Website https://www.vynetherapeutics.com
Analyst Forecast
According to 2 analyst ratings, the average rating for VYNE stock is "Buy." The 12-month stock price forecast is $6.88, which is an increase of 130.87% from the latest price.
Buy 100.00%
Hold 0.00%
Sell 0.00%
Next Earnings Release
VYNE Therapeutics Inc. is scheduled to release its earnings on Feb 27, 2025,
before market opens.
Analysts project revenue of $200.00K, reflecting a 163.16% YoY growth and earnings per share of -0.25, making a 38.89% increase YoY.
Analysts project revenue of $200.00K, reflecting a 163.16% YoY growth and earnings per share of -0.25, making a 38.89% increase YoY.
